VCMCVC Market Cap
Menu

Baseimmune valuation, funding and investors

baseimmune.co.uk ↗LinkedIn ↗

Baseimmune works in active immunotherapy development, based in London, United Kingdom. Founded in 2019, it has about 29 employees.

Biotechnology London Series A
VALUATION · TODAY
$112M −27% after Series A
Range $24.1M – $159M · Grade C
TODAY
+12 MO
$50.0M
$100M
$150M
$200M
2020
2021
2022
2023
2024
2025
2026
2027
Seed $0.94M
Series A $11.3M
ValuationBefore first round12-month outlook: where it points, how wide it fansHover the past: the outlook shows what was predicted then
HEADCOUNT · TODAY29 employees
+0%6m growth
+16%1y growth
+45%2y growth
20
40
Data from Feb 2022
TODAY
Predicted in 1 yr $81.2M −27% vs today
Predicted next raise $17.1M if a round comes
Winding-down probability 0%
Last round
Series A · $11.3M · Feb 2024
Valuation at last round
$56.0M · implied
Headcount
29 · up
Grade
C
Founded
2019
How VCMC values companies →

Baseimmune valuation today

VCMC values Baseimmune at $112M today, with a range of $24.1M to $159M and a grade of C. The valuation starts from its last funding round, a Series A round in Feb 2024.

Valuation by date (97 rows)

Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.

Baseimmune: valuation by date, as the model would have shown it on each date
DateValuationRangePredicted in 1 yrPhaseHeadcountTrendGradeWinding-down probability
1 Jan 2019$7.76M$2.83M – $21.3M$9.59M (+24%)before first round–unknownD0%
1 Feb 2019$7.97M$2.90M – $21.9M$9.68M (+21%)before first round–unknownD0%
1 Mar 2019$8.17M$2.97M – $22.4M$9.76M (+19%)before first round–unknownD0%
1 Apr 2019$8.39M$3.05M – $23.1M$9.85M (+17%)before first round–unknownD0%
1 May 2019$8.61M$3.14M – $23.7M$9.94M (+15%)before first round–unknownD0%
1 Jun 2019$8.85M$3.22M – $24.3M$10.0M (+13%)before first round–unknownD0%
1 Jul 2019$9.08M$3.30M – $24.9M$10.1M (+11%)before first round–unknownD0%
1 Aug 2019$9.17M$3.34M – $25.2M$10.2M (+11%)before first round–unknownD0%
1 Sep 2019$9.25M$3.37M – $25.4M$10.3M (+11%)before first round–unknownD0%
1 Oct 2019$9.34M$3.40M – $25.6M$10.4M (+11%)before first round–unknownD0%
1 Nov 2019$9.42M$3.43M – $25.9M$10.5M (+11%)before first round–unknownD0%
1 Dec 2019$9.51M$3.46M – $26.1M$10.6M (+11%)before first round–unknownD0%
1 Jan 2020$9.59M$3.49M – $26.4M$10.7M (+11%)before first round–unknownD0%
1 Feb 2020$9.68M$3.52M – $26.6M$10.8M (+11%)before first round–unknownD0%
1 Mar 2020$9.76M$3.55M – $26.8M$10.9M (+11%)before first round–unknownD0%
1 Apr 2020$9.85M$3.59M – $27.1M$11.0M (+11%)before first round–unknownD0%
1 May 2020$9.94M$3.62M – $27.3M$11.1M (+11%)before first round–unknownD0%
1 Jun 2020$10.0M$3.65M – $27.6M$11.2M (+11%)before first round–unknownD0%
1 Jul 2020$10.1M$3.69M – $27.8M$11.3M (+11%)before first round–unknownD0%
1 Aug 2020$10.2M$3.72M – $28.1M$11.4M (+11%)before first round–unknownD0%
1 Sep 2020$10.3M$3.75M – $28.3M$11.5M (+11%)before first round–unknownD0%
1 Oct 2020$10.4M$3.79M – $28.6M$11.6M (+11%)before first round–unknownD0%
1 Nov 2020$10.5M$3.82M – $28.8M$11.7M (+11%)before first round–unknownD0%
1 Dec 2020$10.6M$3.86M – $29.1M$11.8M (+11%)before first round–unknownD0%
1 Jan 2021$10.7M$3.89M – $29.3M$11.9M (+11%)before first round–unknownD0%
1 Feb 2021$10.8M$3.93M – $29.6M$12.0M (+11%)before first round–unknownD0%
1 Mar 2021$10.9M$3.96M – $29.9M$12.1M (+11%)before first round–unknownD0%
1 Apr 2021$4.82M$3.16M – $14.7M$9.63M (+100%)after a round–unknownC0%
2 Apr 2021$4.83M$3.16M – $14.7M$9.63M (+100%)after a round–unknownC0%
1 May 2021$5.10M$3.16M – $14.7M$9.63M (+89%)after a round–unknownC0%
1 Jun 2021$5.41M$3.16M – $14.7M$9.63M (+78%)after a round–unknownC0%
1 Jul 2021$5.72M$3.16M – $14.7M$9.63M (+68%)after a round–unknownC0%
1 Aug 2021$6.07M$3.16M – $14.7M$9.63M (+59%)after a round–unknownC0%
1 Sep 2021$6.44M$3.16M – $14.7M$9.63M (+50%)after a round–unknownC0%
1 Oct 2021$6.82M$3.16M – $14.7M$9.63M (+41%)after a round–unknownC0%
1 Nov 2021$7.23M$3.16M – $14.7M$9.63M (+33%)after a round–unknownC0%
1 Dec 2021$7.65M$3.16M – $14.7M$9.63M (+26%)after a round–unknownC0%
1 Jan 2022$8.12M$3.16M – $14.7M$9.63M (+19%)after a round–unknownC0%
1 Feb 2022$8.61M$3.16M – $14.7M$9.63M (+12%)after a round11unknownC0%
1 Mar 2022$9.08M$3.16M – $14.7M$9.63M (+6%)after a round11unknownC0%
1 Apr 2022$9.63M$3.16M – $14.7M$9.63M (0%)after a round11unknownC0%
1 May 2022$9.63M$3.01M – $14.7M$9.63M (0%)after a round11unknownC0%
1 Jun 2022$9.63M$2.86M – $14.7M$9.63M (0%)after a round11unknownC0%
1 Jul 2022$9.63M$2.73M – $14.7M$9.63M (0%)after a round11unknownC0%
1 Aug 2022$9.63M$2.59M – $14.7M$9.63M (0%)after a round11unknownC0%
1 Sep 2022$9.63M$2.46M – $14.7M$9.63M (0%)after a round11unknownC0%
1 Oct 2022$9.63M$2.34M – $14.7M$9.63M (0%)after a round11unknownC0%
1 Nov 2022$9.63M$2.23M – $14.7M$9.63M (0%)after a round11unknownC0%
1 Dec 2022$9.63M$2.12M – $14.7M$9.63M (0%)after a round11unknownC0%
1 Jan 2023$9.63M$3.29M – $14.7M$9.63M (0%)after a round15growingC0%
1 Feb 2023$9.63M$3.30M – $14.7M$9.63M (0%)after a round15growingC0%
1 Mar 2023$9.63M$3.32M – $14.7M$9.63M (0%)after a round15growingC0%
1 Apr 2023$9.63M$3.33M – $14.7M$9.63M (0%)after a round15growingC0%
1 May 2023$9.63M$2.98M – $14.7M$9.63M (0%)after a round15growingC0%
1 Jun 2023$9.63M$2.97M – $14.7M$9.63M (0%)after a round15growingC0%
1 Jul 2023$9.63M$2.95M – $14.7M$9.63M (0%)after a round15growingC0%
1 Aug 2023$9.63M$2.94M – $14.7M$9.63M (0%)after a round15growingC0%
1 Sep 2023$9.63M$1.35M – $14.7M$9.63M (0%)after a round15unknownD0%
1 Oct 2023$6.10M$1.29M – $11.9M$5.03M (-17%)after a round14flatD34%
1 Nov 2023$6.02M$1.22M – $11.9M$4.94M (-18%)after a round14flatD34%
1 Dec 2023$5.95M$1.16M – $11.9M$4.84M (-19%)after a round14flatD34%
1 Jan 2024$5.88M$1.11M – $12.0M$4.75M (-19%)after a round14flatD34%
1 Feb 2024$5.81M$1.05M – $12.0M$4.65M (-20%)after a round14flatD34%
27 Feb 2024$56.0M$39.5M – $117M$82.3M (+47%)after a round14flatB34%
1 Mar 2024$56.3M$39.5M – $143M$101M (+79%)after a round18upC0%
1 Apr 2024$59.2M$39.5M – $143M$101M (+70%)after a round18upC0%
1 May 2024$62.2M$39.5M – $143M$101M (+62%)after a round18upC0%
1 Jun 2024$65.3M$39.5M – $143M$101M (+54%)after a round18upC0%
1 Jul 2024$68.6M$39.5M – $143M$101M (+47%)after a round18upC0%
1 Aug 2024$72.8M$40.4M – $146M$103M (+42%)after a round20growingC0%
1 Sep 2024$76.7M$40.4M – $146M$103M (+35%)after a round20growingC0%
1 Oct 2024$80.6M$40.4M – $146M$103M (+28%)after a round20growingC0%
1 Nov 2024$86.7M$41.6M – $151M$106M (+23%)after a round23growingC0%
1 Dec 2024$91.4M$41.6M – $151M$106M (+16%)after a round23growingC0%
1 Jan 2025$96.5M$41.6M – $151M$106M (+10%)after a round23growingC0%
1 Feb 2025$102M$41.6M – $151M$106M (+4%)after a round23growingC0%
1 Mar 2025$106M$41.7M – $151M$106M (0%)after a round23growingC0%
1 Apr 2025$106M$42.3M – $151M$106M (0%)after a round23growingC0%
1 May 2025$106M$40.8M – $151M$106M (0%)after a round23upC0%
1 Jun 2025$106M$40.4M – $151M$106M (0%)after a round23upC0%
1 Jul 2025$109M$45.3M – $155M$109M (0%)after a round26growingC0%
1 Aug 2025$111M$46.7M – $158M$111M (0%)after a round28growingC0%
1 Sep 2025$109M$46.7M – $155M$109M (0%)after a round26growingC0%
1 Oct 2025$108M$39.7M – $154M$108M (0%)after a round25upC0%
1 Nov 2025$108M$39.3M – $154M$108M (0%)after a round25upC0%
1 Dec 2025$108M$39.0M – $154M$108M (0%)after a round25upC0%
1 Jan 2026$108M$38.6M – $154M$108M (0%)after a round25upC0%
1 Feb 2026$108M$38.2M – $154M$108M (0%)after a round25upC0%
1 Mar 2026$108M$23.1M – $154M$108M (0%)after a round25flatC0%
1 Apr 2026$112M$29.5M – $159M$112M (0%)after a round29upC0%
1 May 2026$112M$28.7M – $159M$111M (-1%)after a round29upC0%
1 Jun 2026$112M$27.8M – $159M$110M (-2%)after a round29upC0%
1 Jul 2026$112M$27.0M – $159M$109M (-2%)after a round29upC0%
1 Aug 2026$112M$26.2M – $159M$109M (-3%)after a round29upC0%
1 Sep 2026$112M$25.4M – $159M$108M (-3%)after a round29upC0%
1 Oct 2026$112M$24.6M – $159M$108M (-4%)after a round29upC0%
24 Oct 2026$112M$24.1M – $159M$81.2M (-27%)after a round29upC0%

Key facts about Baseimmune

Founded
2019
Headquarters
London, United Kingdom
Employees
about 29 +4% in a year
Total raised
$17M
Funding rounds
3
Last round
Series A Feb 2024

Baseimmune was founded in 2019 by Hussein Kanji and Joshua Blight.

Baseimmune funding history

Baseimmune has 3 funding rounds on record, from Apr 2021 to Feb 2024, $17M in total. None disclosed a valuation.

  1. Series A 26 Feb 2024

    Led by MSD Global Health Innovation Fund, IQ Capital; with Hoxton Ventures, The Creator Fund, BEAST, Maki.vc, AME Cloud Ventures, Founders Fund, HCVC, LAUNCHub, Marathon Venture Capital.

    Sources: globenewswire.com, businesswire.com, taylorwessing.com

    $11M

  2. Other 2 Nov 2021no round page

    Led by Hoxton Ventures; with The Creator Fund, Cherry Ventures, Best Ventures, Rockmount Capital, Maki.vc, BEAST.

    Sources: p4precisionmedicine.co.uk, uktech.news, uk.finance.yahoo.com and 1 more

    $4.8M

  3. Seed 1 Apr 2021

    Led by The Creator Fund; with Maki.vc, Rockmount Capital, Vaccitech, Oxford University.

    Sources: baseimmune.co.uk

    $945K

Baseimmune investors

16 investors have backed Baseimmune; The Creator Fund, Hoxton Ventures and IQ Capital and 1 more led at least one round.

What Baseimmune does

Baseimmune works in biotechnology, with 6 recorded offerings and customers in biotechnology and healthcare.

Baseimmune Ltd is a British biotechnology company engaged in the development of active immunotherapies and the creation of bespoke antigens through computational design and protein engineering. The company conducts research and development in vaccine discovery and therapeutic antigen production, with a focus on addressing chronic diseases. Baseimmune also operates as a provider of biotechnology services and maintains a presence at the London Bioscience Innovation Centre.

Description from Veridion's company data.

Products and services

  • Active Immunotherapy Development
  • Bespoke Antigen Discovery and Engineering
  • Computational Antigen Design Services
  • Vaccine Platform Development
  • Chronic Disease Therapy Research
  • Immunotherapy Technology Innovation

Markets

  • Biotechnology
  • Healthcare

Technology

  • Computational Design for Antigen Development
  • Protein Engineering for Antigen Development

Certifications

  • GDPR compliant

Business model

  • Business-to-Business
  • Manufacturing

Industry codes (NAICS)

  • 541714 Research and Development in Biotechnology (except Nanobiotechnology) 100% match

Questions about Baseimmune

What is Baseimmune worth?

Valuation $112M (range $24.1M to $159M), as of 24 Oct 2026.

Has Baseimmune raised money?

Baseimmune has 3 funding rounds on record, from Apr 2021 to Feb 2024, $17M in total. None disclosed a valuation.

Who has invested in Baseimmune?

The Creator Fund, Hoxton Ventures, IQ Capital, MSD Global Health Innovation Fund, Maki.vc and BEAST, and 10 more. Lead investors include The Creator Fund, Hoxton Ventures, IQ Capital and MSD Global Health Innovation Fund.

How many people work at Baseimmune?

About 29, up 4% over the last year. Headcount grew from 11 in Feb 2022 to 29 in Sep 2026.

What does Baseimmune do?

Baseimmune works in biotechnology, with 6 recorded offerings and customers in biotechnology and healthcare. Its main offerings are active immunotherapy development, bespoke antigen discovery and engineering and computational antigen design services.

When was Baseimmune founded, and where is it based?

Baseimmune was founded in 2019 and is based in London, United Kingdom. It has about 29 employees, up 4% over the last year.

How we value companiesReport an issue